



29 January 2024

cyclo**medica**  
techne**gas**

The Manager  
Company Announcements Office  
Australian Securities Exchange Limited  
20 Bridge Street  
Sydney NSW 2000

Cyclopharm Ltd  
ABN 74 116 931 250  
Unit 4, 1 The Crescent  
Kingsgrove NSW 2208 Australia  
T 61 2 9541 0411  
F 61 2 9543 0960  
[www.cyclopharm.com.au](http://www.cyclopharm.com.au)

## **STRATEGIC PARTNERSHIP: CYCLOPHARM TO INSTALL TECHNEGAS AT YALE'S TRANSLATIONAL RESEARCH IMAGING CENTER**

Dear Cyclopharm Shareholders,

We are thrilled to share a development that exemplifies Cyclopharm's commitment to advancing medical research and innovation. Today, we announce an impactful collaboration between Cyclopharm and the Yale Translational Research Imaging Center (Y-TRIC), a distinguished institution at the forefront of medical imaging research.

In this groundbreaking collaboration, Y-TRIC will harness the power of Cyclopharm's cutting-edge nuclear medicine lung ventilation imaging agent, Technegas, in their pioneering research on Acute Respiratory Distress Syndrome (ARDS), a known life threatening complication of COVID-19. The use of Technegas in this critical research has the potential to deepen the understanding of ARDS and contribute to the development of enhanced diagnostic and therapeutic solutions. Investigators in Y-TRIC will also be applying Technegas in studies of other debilitating conditions like pulmonary hypertension and heart failure.

We are delighted to share that Dr. Albert Sinusas MD, FACC, FAHA, Professor of Medicine and Radiology & Biomedical Imaging and Biomedical Engineering at Yale University, has expressed his longstanding interest in incorporating Technegas into his research. Dr. Sinusas notes, "I have been intrigued by the potential of Technegas for our ongoing research for several years. Following FDA approval, I am pleased to see that this advanced imaging agent is now available in the USA."

Technegas, with its distinctive attributes, has proven to be an invaluable tool in pulmonary imaging, providing clinicians and researchers with high-quality, reliable data throughout the world. This collaboration not only emphasises Cyclopharm's dedication to supporting initiatives that advance medical knowledge but also positions us as a key partner in cutting-edge medical research in 'Beyond PE' applications.

We are delighted to announce that the installation of Technegas at Y-TRIC, scheduled for later this week, will be conducted under commercial terms, underscoring the mutually beneficial nature of this collaboration. This arrangement not only reinforces the value of Technegas but also underscores Cyclopharm as a key player in the realm of nuclear, cardiac and respiratory medicine.

This partnership aligns seamlessly with Cyclopharm's overarching mission to make a meaningful impact on global healthcare by offering novel solutions for respiratory imaging. We anticipate that

For personal use only

this collaboration will not only elevate the profile of Technegas but also solidify Cyclopharm's position as an innovator in nuclear medicine.

We eagerly anticipate the potential breakthroughs that may emerge from our partnership with investigators at Yale and the positive impact it could have on both our company and, most importantly, the lives of patients.

Thank you for your support as shareholders. We remain steadfast in our commitment to driving value and making a significant difference in the field of medical imaging.

- ENDS -

This ASX announcement was approved and authorised for release by James McBrayer, Managing Director, CEO and Company Secretary.

**For more information, please contact:**

Mr James McBrayer  
Managing Director, CEO and Company Secretary  
Cyclopharm Limited  
T: +61 (02) 9541 0411

**Cyclopharm Limited**

Cyclopharm is an ASX Listed radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas® used in functional lung ventilation imaging.

**Technegas®**

The Technegas® technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,700° C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional ventilation imaging. Historically used in the diagnosis of pulmonary embolism, Technegas®, together with advancements in complementary technology to multimodality imaging and analytical software, is being used in other disease states to include COPD, asthma, pulmonary hypertension, Long COVID and certain interventional applications to include lobectomies in lung cancer and lung volume reduction surgery.